Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10096-020-04078-1 http://scihub22266oqcxt.onion/10.1007/s10096-020-04078-1 33083917!7575217!33083917     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Microbiol+Infect+Dis 2021 ; 40 (4): 761-769 Nephropedia Template TP {{tp|p=33083917|t=2021. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study |pdf=|usr=}}{{33083917}} gab.com Text High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study JO: Eur J Clin Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33083917 #FOAvip Despite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients. We evaluated the mortality, the risk of need for mechanical ventilation (MV), or death and the risk of developing a severe acute respiratory distress syndrome (ARDS) between high (HD) and standard doses (SD) among patients with a severe COVID-19. All consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an ARDS. Patients were allocated to the HD (>/= 250 mg/day of methylprednisolone) of corticosteroids or the SD (</= 1.5 mg/kg/day of methylprednisolone) at discretion of treating physician. Five hundred seventy-three patients were included: 428 (74.7%) men, with a median (IQR) age of 64 (54-73) years. In the HD group, a worse baseline respiratory situation was observed and male gender, older age, and comorbidities were significantly more common. After adjusting by baseline characteristics, HDs were associated with a higher mortality than SD (adjusted OR 2.46, 95% CI 1.59-3.81, p < 0.001) and with an increased risk of needing MV or death (adjusted OR 2.35, p = 0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients. Our real-world experience advises against exceeding 1-1.5 mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients. Twit Text FOAVip High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study ????Eur J Clin Microbiol Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33083917 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33083917 #FOAvip English Wikipedia <ref>{{Cite pmid|33083917}}</ref> High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study #MMPMID33083917 Monreal E; Sainz de la Maza S; Natera-Villalba E; Beltran-Corbellini A; Rodriguez-Jorge F; Fernandez-Velasco JI; Walo-Delgado P; Muriel A; Zamora J; Alonso-Canovas A; Fortun J; Manzano L; Montero-Errasquin B; Costa-Frossard L; Masjuan J; Villar LM Eur J Clin Microbiol Infect Dis 2021[Apr]; 40 (4): 761-769 PMID33083917show ga Despite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients. We evaluated the mortality, the risk of need for mechanical ventilation (MV), or death and the risk of developing a severe acute respiratory distress syndrome (ARDS) between high (HD) and standard doses (SD) among patients with a severe COVID-19. All consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an ARDS. Patients were allocated to the HD (>/= 250 mg/day of methylprednisolone) of corticosteroids or the SD ( |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/complications/mortality[MESH] |Cohort Studies[MESH] |Dose-Response Relationship, Drug[MESH] |Female[MESH] |Glucocorticoids/*administration & dosage[MESH] |Humans[MESH] |Logistic Models[MESH] |Male[MESH] |Methylprednisolone/*administration & dosage[MESH] |Middle Aged[MESH] |Respiration, Artificial/*statistics & numerical data[MESH] |Respiratory Distress Syndrome/*epidemiology/etiology[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]High versus standard doses of corticosteroids in severe COVID-19: a re(epmc).pdf DeepDyve Pubget Overpricing